150
Participants
Start Date
July 24, 2025
Primary Completion Date
May 2, 2027
Study Completion Date
May 2, 2027
Abrocitinib
Abrocitinib administered as liquid oral suspension.
Placebo
Placebo administered as liquid oral suspension.
RECRUITING
Clinexpert Kft., Budapest
NOT_YET_RECRUITING
CHUS - Hospital Clinico Universitario, Santiago de Compostela
RECRUITING
Tribe Clinical Research, LLC, Greenville
RECRUITING
Solutions Through Advanced Research, Jacksonville
RECRUITING
Miami Dermatology and Laser Research, Miami
RECRUITING
Cahaba Dermatology & Skin Health Center, LLC, Birmingham
RECRUITING
Centricity Research Dublin Multispecialty, Dublin
RECRUITING
Centricity Research Columbus Ohio Multispecialty, Columbus
RECRUITING
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
NOT_YET_RECRUITING
Hospital Universitario Miguel Servet, Zaragoza
RECRUITING
Arkansas Research Trials, North Little Rock
RECRUITING
Queen's square Medical Facilities Queen's square Dermatology and Allergology, Yokohama
RECRUITING
Yoshioka Dermatology Clinic, Neyagawa
RECRUITING
Dermatology and Ophthalmology Kume Clinic, Sakai
RECRUITING
Sasamoto Children's Clinic, Setagaya-ku
RECRUITING
Fukuoka National Hospital, Fukuoka
NOT_YET_RECRUITING
Centrum Medyczne Evimed, Warsaw
NOT_YET_RECRUITING
DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska, Chorzów
NOT_YET_RECRUITING
Centrum Medyczne Angelius Provita, Katowice
NOT_YET_RECRUITING
Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak, Lodz
RECRUITING
Dermedic Jacek Zdybski, Ostrowiec Świętokrzyski
Lead Sponsor
Pfizer
INDUSTRY